1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025

  • April 2017
  • 365 pages
  • GlobalData
Report ID: 3465375

Summary

Table of Contents

Search Inside

PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025

Summary
Global HIV therapeutics market was worth approximately US$16.3 billion in 2015, and GlobalData projects this market to reach a total of US$22.5 billion in sales by 2025, at a Compound Annual Growth Rate (CAGR) of 3.3%.

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART).

Some of the main drivers of the growth of the HIV market during the forecast period are expected to be -
- The introduction of novel drugs-most notably, single-tablet regimens (STRs) and nucleotide reverse transcriptase inhibitor (NRTI)-free regimens with improved tolerability, a reduced pill burden, or increased efficacy.
- An increasing number of people living with HIV who are treated with antiretroviral therapy (ART).
- Increased efforts to identify new HIV infections through more aggressive screening and diagnostic policies, along with new and more sensitive diagnostic testing tools and methods.
- Adoption of the test-and-treat approach to increase the number of patients on ART and reduce viral loads.

HIV market is dominated by the Big Pharma players, such as Gilead, ViiV Healthcare (a collaboration between GlaxoSmithKline [GSK], Pfizer, and Shionogi), Janssen, and Merck, and other companies that have carved out a niche in the existing marketplace. While some of the companies involved in the HIV marketplace have invested in their R&D to build exhaustive pipelines spanning all phases of clinical development, others, such as Bristol-Myers Squibb (BMS), moved out of the HIV market in favor of other disease markets, such as oncology.

Two of the most important persistent unmet needs with regard to the current HIV therapies are concerns about drug adverse effects and the need for drugs that are active against drug-resistant strains of HIV. Currently, it is relatively common for drug-resistant viral strains to force physicians to move patients from one therapy to the next, which can result in in the emergence of untreatable strains and restrict the use of the available drugs. This is especially a concern among patients who are treated with a multi-pill regimen, which negatively affects compliance rates.

The report "PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025" provides an overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following -
- Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Gilead Sciences, ViiV Healthcare,Merck & Co. , Janssen (Johnson & Johnson), Bristol-Myers Squibb, TaiMed Biologics, Cytodyn.

Scope
- Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • July 2017
  • by GlobalData

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H2, 2017" provides ...

Cirrhosis Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • June 2017
  • by GlobalData

Cirrhosis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Cirrhosis Global Clinical Trials Review, H1, 2017" provides an overview of Cirrhosis clinical trials scenario. ...

Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • July 2017
  • by GlobalData

Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Cytomegalovirus (CMV) Retinitis Global Clinical Trials Review, H2, 2017" provides ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.